Riskpilot← Back to searchSign inGet full accessGHK INVEST AS
ASActiveOrg 992793120Stakkevollvegen 51, 9010 TromsøManufacture of basic pharmaceutical products · NACE 2110Est. 20080 employees
Revenue 2024
NOK 0
EBITDA margin
—
-74% vs 2023
Equity ratio
78.3%
Financial strength
Net profit 2024
NOK -464K
-2385% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -464K | -74% |
| Net profit | NOK -464K | -2385% |
| Total assets | NOK 9,1M | +18% |
| Equity | NOK 7,2M | -6% |
| Employees | 0 | — |
Legal name
GHK INVEST AS
Org number
992793120
Legal form
Aksjeselskap
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
23. juni 2008
Share capital
NOK 127 257
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Konsulentvirksomhet og investering i andre virksomheter.
Address
Stakkevollvegen 51, 9010 Tromsø
Email
info@ghk.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 175 | 515 | 0 | 0 | 0 |
| Staff expenses | −410 | −395 | −1 096 | −242 | −342 |
| EBITDA | −360 | 63 | −1 155 | −266 | −464 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −360 | 63 | −1 155 | −266 | −464 |
| Net financials | −3 | 1 977 | 2 992 | 286 | 0 |
| Profit before tax | −362 | 2 041 | 1 837 | 20 | −464 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −362 | 2 041 | 1 837 | 20 | −464 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 698 | 7 393 | 8 036 | 7 728 | 9 150 |
| Equity | 3 730 | 5 771 | 7 608 | 7 628 | 7 165 |
| Long-term debt | 750 | 1 551 | 100 | 100 | 1 040 |
| Short-term debt | 218 | 72 | 328 | 0 | 945 |
| Total debt | 968 | 1 623 | 428 | 100 | 1 985 |
EBITDA margin
-46382800.0%
This company
15.8%
Market median
-293562125% vs market
20202024
Equity ratio
78.3%
This company
38.2%
Market median
+105% vs market
20202024
Return on equity
-6.5%
This company
18.4%
Market median
-135% vs market
20202024
Net profit margin
-46366400.0%
This company
8.1%
Market median
-572424791% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 3.14% | 3.14% | 2022 | |
| Company | 1.74% | 1.74% | 2022 | |
| Individual | 1.05% | 1.05% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
GHK INVEST AS (this company)
SCANDIDERMA ASBoard members of GHK INVEST AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kai-Hugo Hebnes | Board of Directors | 0 companies |
| Geir Håvard Kvalheim | Chairman | 0 companies |